568 related articles for article (PubMed ID: 21576002)
1. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.
Patriarca C; Macchi RM; Marschner AK; Mellstedt H
Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002
[TBL] [Abstract][Full Text] [Related]
2. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
3. EpCAM: A new therapeutic target for an old cancer antigen.
Armstrong A; Eck SL
Cancer Biol Ther; 2003; 2(4):320-6. PubMed ID: 14508099
[TBL] [Abstract][Full Text] [Related]
4. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.
Trzpis M; McLaughlin PM; de Leij LM; Harmsen MC
Am J Pathol; 2007 Aug; 171(2):386-95. PubMed ID: 17600130
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
6. Role of the EpCAM (CD326) in prostate cancer metastasis and progression.
Ni J; Cozzi PJ; Duan W; Shigdar S; Graham PH; John KH; Li Y
Cancer Metastasis Rev; 2012 Dec; 31(3-4):779-91. PubMed ID: 22718399
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of EpCAM in cancer and stem cell signaling.
Munz M; Baeuerle PA; Gires O
Cancer Res; 2009 Jul; 69(14):5627-9. PubMed ID: 19584271
[TBL] [Abstract][Full Text] [Related]
8. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.
Matsuda T; Takeuchi H; Matsuda S; Hiraiwa K; Miyasho T; Okamoto M; Kawasako K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S356-64. PubMed ID: 24566863
[TBL] [Abstract][Full Text] [Related]
9. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis.
Spizzo G; Fong D; Wurm M; Ensinger C; Obrist P; Hofer C; Mazzoleni G; Gastl G; Went P
J Clin Pathol; 2011 May; 64(5):415-20. PubMed ID: 21415054
[TBL] [Abstract][Full Text] [Related]
10. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.
Ruf P; Gires O; Jäger M; Fellinger K; Atz J; Lindhofer H
Br J Cancer; 2007 Aug; 97(3):315-21. PubMed ID: 17622246
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
[TBL] [Abstract][Full Text] [Related]
13. Catumaxomab: clinical development and future directions.
Linke R; Klein A; Seimetz D
MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
[TBL] [Abstract][Full Text] [Related]
14. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma.
Eichelberg C; Chun FK; Bedke J; Heuer R; Adam M; Moch H; Terracciano L; Hinrichs K; Dahlem R; Fisch M; Schlomm T; Sauter G; Minner S
Int J Cancer; 2013 Jun; 132(12):2948-55. PubMed ID: 23180689
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
16. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors.
Rao CG; Chianese D; Doyle GV; Miller MC; Russell T; Sanders RA; Terstappen LW
Int J Oncol; 2005 Jul; 27(1):49-57. PubMed ID: 15942643
[TBL] [Abstract][Full Text] [Related]
17. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D; Lindhofer H; Bokemeyer C
Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
[TBL] [Abstract][Full Text] [Related]
18. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
[TBL] [Abstract][Full Text] [Related]
19. The tumor antigen EpCAM: tetraspanins and the tight junction protein claudin-7, new partners, new functions.
Le Naour F; Zoller M
Front Biosci; 2008 May; 13():5847-65. PubMed ID: 18508627
[TBL] [Abstract][Full Text] [Related]
20. Frequent EpCam protein expression in human carcinomas.
Went PT; Lugli A; Meier S; Bundi M; Mirlacher M; Sauter G; Dirnhofer S
Hum Pathol; 2004 Jan; 35(1):122-8. PubMed ID: 14745734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
